Bristol-Myers Squibb Company
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B |
| Depreciation & Amortization | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637.0M |
| Depreciation | $621.0M | $651.0M | $611.0M | $587.0M | $559.0M | $586.0M | $554.0M | $505.0M |
| Amortization | $3.50B | $9.00B | $9.20B | $9.70B | $10.20B | $9.90B | $1.30B | $198.0M |
| Stock-Based Compensation | $553.0M | $507.0M | $518.0M | $457.0M | $583.0M | $779.0M | $441.0M | $221.0M |
| Net Cash from Operating Activities | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B |
| Investing Activities | ||||||||
| Capital Expenditures | $1.31B | $1.25B | $1.21B | $1.12B | $973.0M | $753.0M | $836.0M | $951.0M |
| Business Acquisitions | $3.94B | $21.82B | $1.17B | $4.29B | $1.61B | $13.08B | $24.78B | $2.37B |
| Net Cash from Investing Activities | $-4.13B | $-21.35B | $-2.30B | $-1.06B | $-538.0M | $-10.86B | $-9.91B | $-2.00B |
| Financing Activities | ||||||||
| Dividends Paid | $5.05B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B |
| Stock Repurchases | $0 | $0 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320.0M |
| Net Cash from Financing Activities | $-10.35B | $5.13B | $-9.42B | $-16.96B | $-16.22B | $-1.15B | $7.62B | $-3.54B |
| Net Change in Cash | $-129.0M | $-1.17B | $2.19B | $-4.99B | $-657.0M | $2.15B | $5.91B | $1.49B |
| Free Cash Flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.37B | $6.12B |